RDIF negotiated production of Sputnik V in Turkey

26 April 2021

The Russian Direct Investment Fund (RDIF) and Turkey’s Viscoran Ilac agreed on the production of Sputnik V Russian vaccine against the coronavirus infection. It is planned to start in the next few months at several facilities, the Fund said in a statement.

 

‘RDIF and Turkish pharmaceutical company Viscoran Ilac announce the collaboration to produce Sputnik V, the world’s first registered vaccine against the coronavirus infection, in the country. Viscoran Ilac has made preparations for localization of production and plans to start production of Sputnik V vaccines at several facilities in the coming months’, the Fund announced.

 

Within the framework of the agreement with RDIF, Viscoran Ilac is also supporting the formation of partnerships with other pharmaceutical manufacturers. In particular, a technology transfer process is being finalized with the CinnaGen Ilac Company and negotiations are ongoing with two other manufacturing sites to expand vaccine production capacity.

 

‘The agreement with Viscoran Ilac is aimed at expanding production capacity and ensuring international supplies of the Sputnik V vaccine. RDIF has entered into agreements with leading pharmaceutical companies in Asia, Latin America, Europe and the CIS, which will make the safe and effective Russian vaccine available to people in more than 60 countries’, RDIF CEO Kirill Dmitriev said.

 

Viscoran Ilac Chairman Ozturk Oran noted that in addition to the agreement for vaccine production, licensing processes, as well as storage and distribution issues, part of the cooperation with Russia is also clinical trials of the vaccine, which are progressing very well.

 

The Sputnik V vaccine has already been approved in 60 countries with a total population of around 3 billion people. Sputnik V has the second highest number of approvals by government regulators in the world. The vaccine’s effectiveness was 97,6% based on the analysis of data from 3,8 million vaccinated Russians, higher than the data previously published by The Lancet medical magazine (91,6%), the Russian Direct Investment Fund (RDIF) and Gamaleya Research Centre reported earlier.

 

GSV "Russia - Islamic World"

Photo: Andrey Luzik\TASS

Based on materials RIA Novosti